Sartorius AG Reports 7.7% Operational Sales Growth in H1 2026, Confirms Full-Year Outlook

Bioprocess Solutions Division Leads Growth with 8.3% Operational Increase

The Bioprocess Solutions Division, accounting for roughly 80% of Group sales, remained the key growth driver in H1 2026. It generated €1,475 million in sales revenue, with operational sales rising 8.3% in constant currencies excluding tariff compensation effects. Underlying EBITDA increased 5.2% to €477 million, and the division’s margin expanded to 32.3% from 31.6% in H1 2025.

During the period, the division broadened its portfolio by launching the Ambr 250 HT Cell Therapies Vessel, designed to enhance process development and scalability in cell therapy manufacturing from early-stage to commercial production. Additionally, the Pionic platform for intensified continuous bioprocessing was expanded with new Quad and Cross modules, enabling flexible multi-column chromatography and integrated ultrafiltration workflows. These innovations underscore the division’s strategic focus on delivering safer, faster, and more sustainable solutions for biotech drugs, vaccines, and cell and gene therapies globally.

Lab Products & Services Division Maintains Stability with Consumables-Driven Recovery

The Lab Products & Services Division, Sartorius’ smaller segment, sustained positive momentum despite margin pressure in H1 2026. It recorded €335 million in sales revenue with 5.3% operational growth in constant currencies after excluding tariff compensation effects. Growth was primarily driven by recurring consumables and services, while the non-recurring laboratory instruments business stabilised further, supported by strong bioanalytics portfolio performance.

Underlying EBITDA for this division was €71 million, down from €74 million the previous year, with a margin of 21.2% compared to 22.3%. Positive volume effects and economies of scale were offset by investments in growth initiatives. The division also launched Cubis III, the latest generation of Sartorius’ premium laboratory balances, designed for demanding lab environments with direct connectivity, built-in compliance, and simplified data management for AI-enabled workflows.

Geographic Growth Across EMEA, Americas, and Asia-Pacific Regions

Sartorius experienced geographically diversified growth in H1 2026. The Europe, Middle East, and Africa (EMEA) region led with €784 million in sales and 7.2% operational growth in constant currencies year-over-year. The Asia-Pacific region accelerated growth to 12.1% in constant currencies, reaching €419 million, driven by ongoing recovery in China after earlier softness. The Americas generated €608 million in sales; excluding tariff compensation, operational growth was 5.6%, while reported growth including compensation was 1.2% in constant currencies.

The company operates about 60 production and sales sites worldwide, enabling it to benefit from diverse market dynamics, including China’s recovery and sustained biopharmaceutical investment in Europe and North America. All regions contributed positively, highlighting the portfolio’s resilience across geographic and customer segments.

U.S. Tariff Refunds Impact Reported First-Half Results

A significant non-operational factor affecting Sartorius’ H1 financials was the receipt of U.S. tariff refunds tied to levies invalidated by the U.S. Supreme Court. Sartorius plans to compensate customers for prior tariff surcharges, leading to reductions in cost of sales and sales revenue. This compensation lowered reported Group sales growth to 6.2% operationally (from 7.7%) and 2.5% reported.

The timing and amount of these refunds were uncertain until their receipt at the end of Q2. CEO Dr. Michael Grosse commented, "It is good to have more clarity now – even though we have seen a non-operating effect on our reported results." Management noted that customer compensation related to unlawful U.S. tariffs could reduce revenue by up to €40 million versus initial expectations, potentially affecting the lower half of guidance ranges for the Group and Bioprocess Solutions Division.

EBITDA Margin Growth and Profitability Boost Investor Confidence

The Group’s underlying EBITDA margin improved by 0.5 percentage points to 30.3% in H1 2026, driven by volume growth and economies of scale that offset product mix and growth investments. Underlying EBITDA rose 3.9% to €548 million, and underlying net profit increased 2% to €172 million. Underlying earnings per ordinary share reached €2.49, up from €2.44, while preference shares earnings rose to €2.50 from €2.45.

Margin development was influenced by offsetting tariff-related effects: headwinds from existing U.S. tariffs and tailwinds from refunds largely balanced out. This stability amid non-operational tariff impacts indicates solid operational fundamentals. Operating cash flow surged 25.9% to €364.4 million, and free cash flow jumped 70.4% to €207.7 million, reflecting better working capital and execution.

Balance Sheet Strengthened with Improved Equity and Leverage Ratios

Sartorius strengthened its balance sheet in H1 2026, with the equity ratio rising to 41.6% as of 30 June from 39.8% at year-end 2025. Total assets stood at €9,601.5 million, and equity reached €3,997.6 million, supporting financial stability and investment capacity.

The leverage ratio (net debt to underlying EBITDA on a rolling 12-month basis including acquisitions) improved to 3.51 from 3.55 at the end of 2025, approaching management’s target of slightly above 3.0 by year-end. Capital expenditure remained steady at €161 million, representing 8.9% of sales revenue. Headcount increased to 14,279 employees from 14,042, mainly due to additional production hires across regions.

MATTEK Acquisition Fuels Lab Division Growth and Microtissue Expansion

The July 2025 acquisition of microtissue specialist MATTEK contributed notably to Lab Products & Services Division growth in H1 2026. MATTEK added 2.8 percentage points to the division’s sales growth and approximately 0.3 percentage points to Group growth. This acquisition enhances Sartorius’ advanced tissue engineering portfolio alongside existing lab instruments and consumables.

Sartorius continues to pursue complementary acquisitions as part of its inorganic growth strategy. MATTEK’s integration supports evolving customer needs in life science research and pharmaceutical labs, especially in 3D cell culture and tissue engineering. Management expects MATTEK to contribute about 1.5 percentage points to Lab Products & Services growth and 0.3 percentage points at Group level for full-year 2026, indicating sustained momentum.

Full-Year 2026 Guidance Reaffirmed Amid Tariff and Geopolitical Challenges

On 23 July 2026, management reaffirmed full-year 2026 guidance, projecting Group sales growth of approximately 5% to 9% in constant currencies, with Bioprocess Solutions expected to grow 6% to 10% and Lab Products & Services 2% to 6%. Operational business excluding tariff effects is forecasted to perform positively and align with initial expectations, with Group and Bioprocess Solutions growth near the midpoint of guidance ranges and Lab Products & Services growth in the upper half.

The guidance acknowledges increased industry volatility and geopolitical uncertainties, including tariff-related impacts. Customer compensation for unlawful U.S. tariffs may reduce revenue by up to €40 million from initial assumptions, potentially placing Group and Bioprocess Solutions growth in the lower half of guidance, with Lab Products & Services around the midpoint. Profitability outlook remains stable, with Group EBITDA margin expected to slightly exceed 30%, Bioprocess Solutions margin above 32%, and Lab Products & Services margin slightly below 21%. The net debt to EBITDA ratio is anticipated to decrease to slightly above 3.0 by year-end.

Strategic Focus on Sustainable Consumables and Process Innovation

Sartorius emphasizes consumables and single-use solutions as safer, faster, and more sustainable options for biopharmaceutical manufacturing. The Bioprocess Solutions Division’s new product launches in H1 2026 highlight this focus, targeting process efficiency, scalability, and data quality. The Ambr 250 HT Cell Therapies Vessel advances upstream bioprocessing, while Pionic platform extensions address intensified downstream processing—both critical as manufacturers seek cost-effective, sustainable production.

The Lab Products & Services Division’s launch of Cubis III reflects a commitment to digitally enabled lab solutions aligned with AI and data analytics workflows. These initiatives address regulatory demands for transparency, scalability needs in cell and gene therapies, and the industry’s shift toward automated, data-rich manufacturing. Recurring consumables remain the main growth driver across divisions, providing revenue stability and customer loyalty amid cyclical capital equipment spending.

Investor Insights and Market Position

As a leading global partner in biopharmaceutical research and manufacturing with approximately 60 production and sales locations, Sartorius is well positioned to capture sustained demand amid complex manufacturing challenges. H1 results demonstrate operational resilience with 7.7% growth in constant currencies despite tariff headwinds and macroeconomic pressures. Margin stability and strong cash flow generation indicate robust underlying profitability.

Investors will monitor consumables growth relative to equipment stabilisation, MATTEK integration progress, tariff-related customer compensation impacts, and progress toward the leverage target of net debt to EBITDA slightly above 3.0. The reaffirmed full-year guidance and CEO Dr. Michael Grosse’s remarks that "the recurring business was the main growth driver" and that "equipment and instruments business stabilised further, even returning to slight growth" suggest confidence in sustained momentum for the second half of 2026. Sartorius plans to release nine-month results for January to September 2026 on 22 October 2026, providing an interim update.